-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Amgen, Raises Price Target to $457

Benzinga·08/20/2026 16:24:51
Listen to the news
Piper Sandler analyst David Amsellem maintains Amgen (NASDAQ:AMGN) with a Overweight and raises the price target from $427 to $457.